DNA treatment cuts bad cholesterol by nearly 50% without statins
Researchers have developed a new DNA-based treatment using polypurine hairpins to suppress the PCSK9 protein, which helps lower bad cholesterol levels. This experimental approach offers a potential alternative to traditional statins for managing cardiovascular health.
Why it matters
Developing non-statin therapies for cholesterol management provides new options for patients who may not respond well to existing treatments or who are at high risk for heart disease.
High cholesterol can quietly damage arteries for years, raising the risk of heart disease and other cardiovascular problems. Now, researchers from the University of Barcelona and the University of Oregon have developed an experimental strategy that could offer a new way to bring cholesterol levels down.
The approach targets PCSK9, a protein that plays a major role in controlling levels of low-density lipoprotein cholesterol (LDL-C), often called "bad" cholesterol. By suppressing PCSK9, the treatment helps cells remove more cholesterol from the bloodstream, potentially reducing the buildup of fatty plaques inside arteries that can lead to atherosclerosis.
Instead of relying on statins, the researchers used molecules called polypurine hairpins (PPRH). These specially designed DNA molecules can interfere with the activity of specific genes. In this case, they were used to reduce production of PCSK9.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in